Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The UNIVERSAL2 study is a research project designed to evaluate a newly developed formulation
of an approved drug for children living with HIV aged over 3 years and weighing between 10
and 25 kg. The aim of UNIVERSAL2 is to determine the right dosage of this new formulation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
PENTA Foundation
Collaborators:
AMS-PHPT Research Collaboration Baylor College of Medicine Centre Hospitalier National d'Enfants Albert Royer Centre Mère et Enfant de la Fondation Chantal Biya Institut National de la Santé Et de la Recherche Médicale, France University of Zimbabwe Clinical Research Centre (UZCRC)